Although the first ADC was approved for HER2-overexpressing breast tumors, preclinical data demonstrated activity of ADCs even in tumors with lower HER2 expression levels, regardless of the hormone receptor status [28]. The gene discussed is NR4A1; the disease is breast neoplasm.